vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and MACOM Technology Solutions Holdings, Inc. (MTSI). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $271.6M, roughly 1.0× MACOM Technology Solutions Holdings, Inc.). MACOM Technology Solutions Holdings, Inc. runs the higher net margin — 18.0% vs -45.7%, a 63.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 24.5%). MACOM Technology Solutions Holdings, Inc. produced more free cash flow last quarter ($30.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 22.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
MACOM Technology Solutions, Inc. is an American developer and producer of radio, microwave, and millimeter wave semiconductor devices and components. The company is headquartered in Lowell, Massachusetts, and in 2005 was Lowell's largest private employer. MACOM is certified to the ISO 9001 international quality standard and ISO 14001 environmental standard. The company has design centers and sales offices in North America, Europe, Asia and Australia.
GH vs MTSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $271.6M |
| Net Profit | $-128.5M | $48.8M |
| Gross Margin | 64.6% | 55.9% |
| Operating Margin | -43.0% | 15.9% |
| Net Margin | -45.7% | 18.0% |
| Revenue YoY | 39.4% | 24.5% |
| Net Profit YoY | -15.8% | 129.1% |
| EPS (diluted) | $-1.01 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $271.6M | ||
| Q4 25 | $281.3M | $261.2M | ||
| Q3 25 | $265.2M | $252.1M | ||
| Q2 25 | $232.1M | $235.9M | ||
| Q1 25 | $203.5M | $218.1M | ||
| Q4 24 | $201.8M | — | ||
| Q3 24 | $191.5M | $200.7M | ||
| Q2 24 | $177.2M | $190.5M |
| Q1 26 | — | $48.8M | ||
| Q4 25 | $-128.5M | $45.1M | ||
| Q3 25 | $-92.7M | $36.5M | ||
| Q2 25 | $-99.9M | $31.7M | ||
| Q1 25 | $-95.2M | $-167.5M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $29.4M | ||
| Q2 24 | $-102.6M | $19.9M |
| Q1 26 | — | 55.9% | ||
| Q4 25 | 64.6% | 54.5% | ||
| Q3 25 | 64.7% | 55.3% | ||
| Q2 25 | 65.0% | 55.2% | ||
| Q1 25 | 63.3% | 53.7% | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | 54.7% | ||
| Q2 24 | 59.1% | 53.2% |
| Q1 26 | — | 15.9% | ||
| Q4 25 | -43.0% | 15.2% | ||
| Q3 25 | -37.3% | 14.9% | ||
| Q2 25 | -45.9% | 14.8% | ||
| Q1 25 | -54.6% | 8.0% | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | 13.7% | ||
| Q2 24 | -56.8% | 10.4% |
| Q1 26 | — | 18.0% | ||
| Q4 25 | -45.7% | 17.3% | ||
| Q3 25 | -35.0% | 14.5% | ||
| Q2 25 | -43.0% | 13.4% | ||
| Q1 25 | -46.8% | -76.8% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 14.7% | ||
| Q2 24 | -57.9% | 10.5% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $-1.01 | $0.67 | ||
| Q3 25 | $-0.74 | $0.48 | ||
| Q2 25 | $-0.80 | $0.42 | ||
| Q1 25 | $-0.77 | $-2.30 | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | $0.40 | ||
| Q2 24 | $-0.84 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $768.5M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.4B |
| Total Assets | $2.0B | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $768.5M | ||
| Q4 25 | $378.2M | $786.0M | ||
| Q3 25 | $580.0M | $735.2M | ||
| Q2 25 | $629.1M | $681.5M | ||
| Q1 25 | $698.6M | $656.5M | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | $581.9M | ||
| Q2 24 | $933.7M | $521.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $-99.3M | $1.3B | ||
| Q3 25 | $-354.5M | $1.3B | ||
| Q2 25 | $-305.5M | $1.2B | ||
| Q1 25 | $-250.8M | $1.2B | ||
| Q4 24 | $-139.6M | — | ||
| Q3 24 | $-60.1M | $1.1B | ||
| Q2 24 | $-1.6M | $1.1B |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.0B | $2.1B | ||
| Q3 25 | $1.3B | $2.0B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.6B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $42.9M |
| Free Cash FlowOCF − Capex | $-54.2M | $30.0M |
| FCF MarginFCF / Revenue | -19.3% | 11.0% |
| Capex IntensityCapex / Revenue | 9.9% | 4.8% |
| Cash ConversionOCF / Net Profit | — | 0.88× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $161.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $42.9M | ||
| Q4 25 | $-26.4M | $69.6M | ||
| Q3 25 | $-35.4M | $60.4M | ||
| Q2 25 | $-60.3M | $38.7M | ||
| Q1 25 | $-62.7M | $66.7M | ||
| Q4 24 | $-64.5M | — | ||
| Q3 24 | $-51.1M | $62.3M | ||
| Q2 24 | $-94.0M | $49.0M |
| Q1 26 | — | $30.0M | ||
| Q4 25 | $-54.2M | $49.4M | ||
| Q3 25 | $-45.8M | $51.6M | ||
| Q2 25 | $-65.9M | $30.5M | ||
| Q1 25 | $-67.1M | $61.3M | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | $57.1M | ||
| Q2 24 | $-99.1M | $41.5M |
| Q1 26 | — | 11.0% | ||
| Q4 25 | -19.3% | 18.9% | ||
| Q3 25 | -17.3% | 20.5% | ||
| Q2 25 | -28.4% | 12.9% | ||
| Q1 25 | -33.0% | 28.1% | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | 28.5% | ||
| Q2 24 | -55.9% | 21.8% |
| Q1 26 | — | 4.8% | ||
| Q4 25 | 9.9% | 7.7% | ||
| Q3 25 | 3.9% | 3.5% | ||
| Q2 25 | 2.4% | 3.5% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | 2.6% | ||
| Q2 24 | 2.9% | 3.9% |
| Q1 26 | — | 0.88× | ||
| Q4 25 | — | 1.54× | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.12× | ||
| Q2 24 | — | 2.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
MTSI
| Industrial Defense | $117.7M | 43% |
| Data Center | $85.8M | 32% |
| Telecom | $68.1M | 25% |
